Published in Cancer Weekly, February 5th, 2008
"Subsequently, molecularly defined vaccines made from proteins, peptides, or gangliosides were developed and, recently, DNA-based vaccines are currently being tested. Randomized trials using allogeneic melanoma cells/lysates or gangliosides have not demonstrated a clinical benefit, although in some trials, clinical benefit was seen in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.